Dr. Reddy’s Expands Access to Immunotherapy for Rare Head and Neck Cancer
JOHANNESBURG, South Africa / HYDERABAD, India, Aug. 3, 2026 Dr. Reddy’s Laboratories South Africa announced the registration of an...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
JOHANNESBURG, South Africa / HYDERABAD, India, Aug. 3, 2026 Dr. Reddy’s Laboratories South Africa announced the registration of an...
HYDERABAD, India, Aug. 1, 2026 Dr. Reddy’s Laboratories Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
ROCKVILLE, Md. and TOKYO, July 30, 2026 Kaigene has entered into an exclusive licensing agreement with Taisho Pharmaceutical Co.,...
WILMINGTON, Del., July 29, 2026 Incyte announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the...
VANCOUVER, British Columbia, July 29, 2026 AbCellera Biologics Inc. announced a strategic collaboration with Vertex Pharmaceuticals to research, develop,...
Amsterdam, the Netherlands and Dallas, Texas – July 27, 2026 argenx has entered into a definitive agreement to acquire...
LONDON, United Kingdom, July 13, 2026 The Alzheimer’s Association has announced the launch of the PROTECT-Cog Study (Prevention of...
SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...
SAN DIEGO, California, July 13, 2026 Aethlon Medical, Inc. has announced encouraging interim findings from the second patient cohort...
DUBLIN, Ireland, July 13, 2026 Keenova Therapeutics plc has announced the publication of a new peer-reviewed real-world evidence study...
